Key Summary Points {#FPar1}
==================

**Why carry out this study?**Sulfonylureas are consistently the most common choice for second-line therapy in patients with type 2 diabetes mellitus (T2DM) who require additional glucose-lowering during metformin monotherapy.In this article we describe presentations given at a symposium held at the International Diabetes Federation Congress in Busan, South Korea (December 2019) that examined the place of sulfonylureas generally, and gliclazide modified release (MR) specifically, in the current treatment paradigm for people with T2DM.**What was learned from the study?**Newer generation sulfonylureas, such as gliclazide MR, are effective, well-tolerated and accessible treatments for T2DM, and recommended in the early management of people with T2DM.Among the available sulfonylureas, gliclazide is associated with the greatest beneficial impact on cardiovascular mortality, and the lowest incidence of severe hypoglycaemia.

Introduction {#Sec1}
============

Sulfonylureas have been used clinically to treat type 2 diabetes mellitus (T2DM) since the 1960s \[[@CR1]\], and are still among the most commonly prescribed oral diabetic treatments \[[@CR2]\]. Data on prescription patterns globally show that sulfonylureas are consistently the most common choice for second-line therapy in patients who require additional glucose-lowering during metformin monotherapy, followed by dipeptidyl peptidase 4 inhibitors (DPP-4i) \[[@CR2], [@CR3]\].

Treatment guidelines for T2DM are regularly updated to include emerging treatments and evolving evidence, especially from cardiovascular outcomes trials (CVOTs). Yet, there are significant differences between guidelines in the recommendations related to sulfonylureas \[[@CR4]--[@CR11]\].

In this article, we describe presentations at a symposium held at the International Diabetes Federation Congress in Busan, South Korea on 4 December 2019. These presentations examined the place of sulfonylureas generally, and gliclazide modified release (MR) specifically, in the current treatment paradigm for people with T2DM. Guideline recommendations for the use of sulfonylureas are described and the evidence supporting these recommendations is critically evaluated, and recent real-world evidence is reviewed on the efficacy and safety of gliclazide MR, including in special populations of patients, such as T2DM patients who undertake daytime fasting during Ramadan and patients with maturity onset diabetes in the young (MODY).

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by the authors.

Place of Sulfonylureas in Current Treatment Guidelines {#Sec2}
======================================================

Diabetes guidelines worldwide almost universally recommend metformin as the first-line glucose-lowering drug in newly diagnosed patients with T2DM, but they vary in terms of the recommendations about which agents should be used as add-on therapies if metformin alone cannot achieve glycaemic targets (Table [1](#Tab1){ref-type="table"}) \[[@CR4]--[@CR6], [@CR8], [@CR10]--[@CR12]\]. In patients with established atherosclerotic cardiovascular disease, recent guidelines consistently recommend second-line treatment with a sodium-glucose cotransporter 2 inhibitor (SGLT-2i) or a glucagon-like peptide-1 receptor agonist (GLP-1RA) \[[@CR6], [@CR8], [@CR12]\], based on data from the large-scale CVOTs showing that these agents reduced the risk of major adverse cardiovascular events (MACE) in patients with diabetes and cardiovascular disease (CVD) \[[@CR13]--[@CR22]\].Table 1Summary of consensus report recommendations on the use of sulfonylureas and gliclazide MR in patients without established atherosclerotic cardiovascular diseaseDiabetes guidelinesSecond-line treatment recommendation in patients with suboptimal glucose control on metforminGuideline information specific to gliclazide MRUK (NICE/SIGN) 2015^a^ \[[@CR11]\]Add DPP-4i, pioglitazone or SUGLP-1RAs not recommended--South Asian Federation of Endocrine Societies 2015 \[[@CR10]\]Add SU as second-line agents of choiceGliclazide MR or glimepiride are preferred over conventional SUAustralia (RACGP and Diabetes Australia) 2016--2018 \[[@CR5]\]Add SU as second-line agents of choiceAnother agent may be used if SU are contraindicated or not toleratedGliclazide less likely to cause hypoglycaemia compared with glibenclamide or glimepirideGlobal (International Diabetes Federation) 2017 \[[@CR4]\]Preferred add-on therapies are SU (not glibenclamide/glyburide), DPP-4i or SLGT-2i--Global resource-limited settings (WHO) 2018 \[[@CR23]\]Add an SUGliclazide is preferred SU if hypoglycaemia is a concernCanada (Diabetes Canada) 2018 \[[@CR6]\]Add DDP-4i, GLP-1RA, or SGLT-2iIf SU is added to metformin, gliclazide is the first choiceUSA/Europe (ADA/EASD) 2018 \[[@CR8]\]Add SU as second-line agents if cost is a compelling issueReserve SU for fourth-line treatments (after DPP-4i, GLP-1RA, SGLT-2i and/or TZD^b^) if there is a compelling need to minimise hypoglycaemia or weight gainGliclazide not licensed in the US for T2DMEurope (ESC/EASD) 2019 \[[@CR12]\]Add DDP-4i, GLP-1RA, SGLT-2i or TZDReserve SU for fourth-line treatments (after DPP-4i, GLP-1RA, SGLT-2i and/or TZD)If using SU, choose a later generation agent to minimise risk of hypoglycaemia*ADA* American Diabetes Association, *DPP-4i* dipeptidyl peptidase 4 inhibitors, *EASD* European Association for the Study of Diabetes, *ESC* European Society of Cardiology, *GLP-1RA* glucagon-like peptide 1 receptor agonists, *MR* modified release, *NICE* National Institute for Health and Care Excellence, *RACGP* Royal Australian College of General Practitioners, *SGLT-2i* sodium-glucose transport protein 2 inhibitors, *SU* sulfonylurea, *T2DM* type 2 diabetes mellitus, *TZD* thiazolidinedione, *WHO* World Health Organization^a^Updated in 2019^b^TZDs not recommended when there is a compelling need to minimise weight gain

For patients without established CVD, the recommendations for add-on glucose-lowering therapy differ between guidelines. Australian, Indian and World Health Organization guidelines specify sulfonylureas as the agents of choice for second-line therapy \[[@CR5], [@CR10], [@CR23]\], while guidelines from the National Institute for Health and Care Excellence (NICE) in the UK and the International Diabetes Federation (IDF) include sulfonylureas as one of the preferred options, along with a DPP-4i and either pioglitazone (UK) or a SGLT-2i (IDF) \[[@CR4], [@CR11]\]. In contrast, the consensus report from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) recommends sulfonylureas as second-line therapy only if cost is a compelling issue \[[@CR8]\]. These consensus recommendations, as well as joint guidelines from the EASD and the European Society of Cardiology (ESC), place sulfonylureas as a fifth-line treatment after other classes of oral glucose-lowering drugs have been tried \[[@CR8], [@CR12]\].

Why the Differences Between Guidelines? {#Sec3}
---------------------------------------

Some may speculate that the guidelines recommending sulfonylureas as the preferred second-line agents do so because of cost. Certainly, sulfonylureas have a low drug acquisition cost compared with other classes of glucose-lowering agents \[[@CR24]\], but to consider that the recommendations are driven by cost alone ignores the well-established efficacy and safety profile of sulfonylureas. As a class, these agents differ in their pharmacokinetic characteristics (Table [2](#Tab2){ref-type="table"}) \[[@CR10], [@CR25]\]. The recommendation for sulfonylureas in the Canadian guidelines is based on a thorough assessment of clinical benefits, quality of life, safety concerns, cost and resource use undertaken by the Canadian Agency for Drugs and Technologies in Health (CADTH) \[[@CR26]\]. This analysis found that the sulfonylurea gliclazide ranked number one in all comparisons because it worked as well as other classes of glucose-lowering drugs but cost the least \[[@CR26]\]. Another reason for the difference between consensus recommendations may be related to the way in which they are developed. Not all reports are developed using strict rigour in their collection and/or assessment of the evidence. In the ADA/EASD guidelines, for example, the authors themselves write: "...though evidence based, the recommendations presented herein are the opinions of the authors" \[[@CR8]\]. Various bodies have developed standards for clinical practice guidelines, including the Institute of Medicine in the USA \[[@CR27]\] and the Appraisal of Guidelines for Research and Evaluation (AGREE) consortium in Canada \[[@CR28]\]. These standards focus on the process, sources, flexibility, validity, reliability and applicability of the recommendations \[[@CR27]\], and have led to the development of the AGREE II instrument that can be used to rate the quality of clinical guidelines \[[@CR28]\]. Using this instrument, the IDF ranked the recommendations from a variety of different bodies \[[@CR4]\]: the highest ranked guidelines for diabetes were the NICE guidelines from the UK (97%), which recommend sulfonylureas as the first choice for add-on therapy. In contrast, the ADA guidelines and the American Association for Clinical Endocrinology (AACE) guidelines scored a total of 50 and 36%, respectively, with particularly low scores for scientific rigour (28% for ADA and 6% for AACE guidelines) \[[@CR4]\]. This suggests that the reputation and popularity of the organisation developing the guidelines may not necessarily reflect the level of the evidence used to make the recommendations.Table 2Features of the different agents in the sulfonylurea drug classFeatures of the agentsAgents in the sulfonylurea drug class^a^TolbutamideChlorpropamideGlibenclamide (glyburide)Glipizide (regular)Gliclazide (regular)GlimepirideGlipizide GITSGliclazide MRGenerationFirstFirstSecondSecondSecondThirdThirdThirdDuration of action categoryShortLongLongIntermediateIntermediateLongLongLongDuration of action (h)Short ≥ 2416--2412--2410--2424 \> 24 \> 24Time to peak plasma level (h)3--42--42--41--34--62--36--126--7Excretion100% renal80--90% renal50% renal80% renal80% renal60% renal80% renal, 10% faecal \< 60--70% renal, 10--20% faecalActive metabolitesNoYesYesNoNoYesNoNoUse in patients with renal dysfunctionAvoidDecrease dose by 50% if GFR 50--70 mL/min/1.73 m^2^Avoid if GFR \< 50 mL/min/1.73 m^2^AvoidNo dose adjustment neededNo dose adjustment neededStart at low doseNo dose adjustment neededNo dose adjustment needed*GITS* Gastrointestinal therapeutic system, *GFR* golemerular filtration rate^a^References: \[[@CR10], [@CR25]\]

Sulfonylureas and Cardiovascular Disease {#Sec4}
----------------------------------------

The EASD/ADA and ESC/EASD consensus guidelines recommend second-line treatment with newer agents (SGLT-2i and GLP-1RA) based on the evidence from CVOTs \[[@CR8], [@CR12]\]. These guidelines reserve sulfonylureas for fifth-line therapy after newer agents have been tried, and cite results from observational studies which suggest an increased risk of CVD with sulfonylureas compared with other classes of glucose-lowering drugs \[[@CR29], [@CR30]\].

However, the compelling benefit of SGLT-2i and GLP-1RAs has only been demonstrated in patients with established CVD---and not in patients with multiple risk factors for CVD \[[@CR31]\]. Moreover, most T2DM patients seen in clinical practice (60--92%) would not meet the eligibility criteria for inclusion SGLT-2i or GLP-1RA CVOTs due to their disease characteristics/comorbid conditions \[[@CR32]--[@CR37]\], calling into question the generalisability of these studies to a wider clinical practice population.

The risk of CVD seen with sulfonylureas in some observational studies \[[@CR38], [@CR39]\] has not been demonstrated in randomised controlled trials (RCTs), including the TOSCA-IT, CAROLINA, ADVANCE and ADOPT studies \[[@CR40]--[@CR43]\]. TOSCA.IT and CAROLINA showed that a sulfonylurea was noninferior to pioglitazone and linagliptin, respectively, for preventing MACE \[[@CR41], [@CR42]\]. In the CAROLINA study, not only was the incidence of the composite endpoint of MACE similar in the sulfonylurea (glimepiride) and DPP-4i arms, but so was the incidence of each individual component of the composite endpoint (cardiovascular death, nonfatal myocardial infarction \[MI\], and nonfatal stroke) \[[@CR41]\]. Importantly, data from a retrospective analysis of real-world outcomes suggest that sulfonylureas and DPP-4i do indeed have a similar impact on cardiovascular outcomes, as seen in the CAROLINA study \[[@CR44]\].

It is also worth noting that sulfonylureas were the major second-line class of glucose-lowering agents used in the large-scale trials that demonstrated the importance of intensive glucose-lowering for delaying the development of macrovascular events in patients with T2DM, such as the UK Prospective Diabetes Study (UKPDS) and ADVANCE \[[@CR45], [@CR46]\]. In ADVANCE, intensive glucose-lowering with a combination metformin + sulfonylurea-based regimen also reduced the risk of microvascular events, and the impact of intensive treatment of microvascular and macrovascular outcomes was similar in patients with different levels of baseline renal function \[[@CR43]\].

Overall, the weight of the evidence indicates no increased risk of mortality or CVD with the use of sulfonylureas compared with other classes of glucose-lowering treatments \[[@CR47]\]. Moreover, examination of the relationship between individual sulfonylureas and CVD outcomes revealed that the lowest risk appears to be associated with gliclazide \[[@CR48]\]. A meta-analysis of sulfonylurea studies demonstrated that gliclazide was associated with a significantly lower risk of cardiovascular mortality (relative risk \[RR\] 0.60; 95% confidence intervals \[CI\] 0.45--00.84) and all-cause mortality (RR 0.65; 95% CI 0.53--0.79) compared with glibenclamide and others (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR48]\].Fig. 1Comparison of all-cause mortality between different sulfonylureas based on direct and indirect evidence \[[@CR48]\]. Data are pooled and analysed by network meta-analysis. Reference agent is glibenclamide.*CV* Cardiovascular. (Reprinted from Lancet Diabetes Endocrinol., \[[@CR48]\] Copyright (2015), with permission from Elsevier)

Sulfonylureas and Severe Hypoglycaemia {#Sec5}
--------------------------------------

Another concern sometimes expressed about the sulfonylureas is the risk of hypoglycaemia. Severe hypoglycaemia is associated with an increased risk of mortality \[[@CR46], [@CR49], [@CR50]\], but no causal relationship between hypoglycaemia and mortality has been proven. A more likely explanation is that severe hypoglycaemia is a marker for comorbidity or illness severity. This is borne out by data from RCTs showing a difference in the incidence of severe hypoglycaemia between treatment arms, but no difference in the risk of CVD or mortality \[[@CR41], [@CR42], [@CR51], [@CR52]\].

For example, in the CAROLINA study, the risk of MACE was similar in the glimepiride and the linagliptin arms (hazard ratio \[HR\] 0.95; 95% CI 0.84--1.14; *p* \< 0.001 for non-inferiority), as was the risk of mortality (HR 0.94; 95% CI 0.78--1.06; *p* = 0.23), but the rate of hypoglycaemia was significantly lower in the linagliptin than in the glimepiride arm (HR 0.23; 95% 0.21--0.26; *p* \< 0.001) \[[@CR41]\]. If hypoglycaemia were causally linked with death, it would be expected that this would be reflected in the mortality outcomes of the CAROLINA study. Another notable element of the CAROLINA study was that it involved a high-risk population for hypoglycaemia, including 35% patients with established CVD, 37% at high cardiovascular risk, 19% aged ≥ 70 years and 18% with stage 3 chronic kidney disease \[[@CR53]\].

In fact, the absolute risk of severe hypoglycaemia with the sulfonylureas in RCTs is low, particularly with the later-generation agents, such as gliclazide (Table [3](#Tab3){ref-type="table"}) \[[@CR41], [@CR42], [@CR54]--[@CR56]\]. Gliclazide is available in a regular, intermediate-acting formulation and a long-acting MR formulation (Table [2](#Tab2){ref-type="table"}). The MR formulation uses a hydrophilic polymer base to release gliclazide progressively over 24 h, allowing once-daily dosing \[[@CR57]\]. Based on the data from randomised trials, at least 232 patients would need to be treated with a sulfonylurea to cause one severe hypoglycaemic event (number needed to harm \[NNH\]), and the NNH for gliclazide MR specifically is 333 \[[@CR41], [@CR42], [@CR54]--[@CR56]\]. The low risk of symptomatic hypoglycaemia is supported by data from a prospective observational study of primary care T2DM patients in the UK \[[@CR58]\]. This study showed a risk of hypoglycaemia (blood glucose \< 3.0 mmol/L) of 0.12 per person-year with sulfonylureas, similar to the rate with incretin-based therapy (0.04 per person-year) and much lower than the rate with insulin (1.03 per person-year) \[[@CR58]\].Table 3Absolute risk of severe hypoglycaemia in randomised controlled trials with sulfonylureasRandomised controlled trialsDuration (years)Treatments*N*Rate of severe hypoglycaemiaGUIDE 2004 \[[@CR56]\]0.52Gliclazide MR4050Glimepiride4400ADVANCE 2008 \[[@CR55]\]5.0Gliclazide MR-based intensive control55712.7Standard control55691.5Foley et al. 2009 \[[@CR54]\]2.0Gliclazide5460Vildagliptin5460TOSCA.IT 2017 \[[@CR42]\]4.8Sulfonylurea^a^14931.61Pioglitazone15350.06CAROLINA 2019 \[[@CR41]\]6.3Glimepiride30102.2Linagliptin30230.1^a^Gliclazide (*n* = 745), glimepiride (*n* = 723) or glibenclamide (*n* = 24) in accordance with local practice

Moreover, the risk of hypoglycaemia varies between sulfonylureas. A recent meta-analysis demonstrated that the relative risk of hypoglycaemia with gliclazide versus placebo (3.9) is more similar to the risk with metformin (2.0) than it is to the risk with other sulfonylureas such as glimepiride (8.9), glyburide (10.2) or glipizide (13.9) \[[@CR59]\]. The risk of hypoglycaemia can be mitigated by avoiding sulfonylureas in high-risk patients, such as elderly or frail patients, those with advanced organ dysfunction or those with a previous history of severe hypoglycaemia.

Sulfonylureas and Weight Gain {#Sec6}
-----------------------------

Another reason why some guidelines may recommend newer agents ahead of sulfonylureas is that SGLT-2i and GLP-1RA are associated with weight loss, while sulfonylureas and thiazolidinediones are associated with modest weight gains \[[@CR59]\]. In clinical trials, the average weight loss was 1.5--2.4 kg with maximal doses of SLGT2i \[[@CR59]--[@CR63]\] and between 0.9 and 1.8 kg with maximal doses of GLP-1RA \[[@CR59]\]. For many patients, weight loss is a desirable side effect of treatment, but there are no data to indicate that the modest loss achieved with SGLT-2i or GLP-1RA contributes to improvements in glycaemic response or clinically measurable outcomes. There was no weight gain with gliclazide MR in the ADVANCE study over a 5-year period.

Role of Sulfonylureas in a Real-World Population {#Sec7}
================================================

As described earlier, the effectiveness and safety of sulfonylureas has been demonstrated in some real-world studies, including data showing that the sulfonylureas and DPP-4i have similar effects on outcomes \[[@CR44]\]. However, data from observational studies performed in the USA using glimepiride may not be applicable in the UK where gliclazide is the most commonly prescribed sulfonylurea.

Use of Sulfonylureas During Ramadan {#Sec8}
===================================

Approximately 1.8 billion people in the world are Muslim. For many of these individuals, fasting during the holy month of Ramadan is an important tenet of their faith, but the requirements of Ramadan (no food or drink during daylight hours) can pose a health risk for Muslim patients with diabetes \[[@CR64]\]. Because the risk of hypoglycaemia is high during fasting, and many Muslim individuals are reluctant to break their fast if they develop hypoglycaemia, optimal care to reduce risks is important. Physicians can minimise the risk by careful treatment choice, risk stratification and patient education, and by encouraging frequent or continuous glucose monitoring during Ramadan \[[@CR64]\].

Patients receiving treatment for T2DM show a higher incidence of hypoglycaemia during Ramadan, and this is true for treatment regimens with or without sulfonylureas \[[@CR65]\]. Randomised studies have shown that the risk of symptomatic hypoglycaemia during Ramadan is low in patients receiving stable doses of a sulfonylurea for at least 3 months, and is lower with gliclazide than with glimepiride or glibenclamide (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR66], [@CR67]\]. In the randomised STEADFAST study, combination therapy with gliclazide + metformin was associated with a similar rate of hypoglycaemia during Ramadan as combination therapy with vildagliptin + metformin \[[@CR68]\]. However, these studies were conducted with short-acting gliclazide, so the effect of a newer formulation of gliclazide, gliclazide MR, on hypoglycaemia during Ramadan is unknown. The DIA-RAMADAN study was the first international real-world study to investigate the effects of gliclazide MR \[[@CR69]\].Fig. 2The incidence of symptomatic hypoglycaemia during Ramadan in patients receiving a SU or sitagliptin in randomised controlled trials. (Data from Al Shifri et al. \[[@CR66]\] and Aravind et al \[[@CR67]\])

The DIA-RAMADAN study was conducted at 64 centres in nine countries (Bangladesh, Egypt, India, Indonesia, Kuwait, Malaysia, Pakistan, Saudi Arabia and the United Arab Emirates) and enrolled 1214 patients with T2DM who had been receiving gliclazide MR 60 mg/day for at least 90 days before enrolment and who planned to fast during Ramadan. Patients completed diaries during the 6--8 weeks before Ramadan, the 4.5 weeks of Ramadan and then for 4--6 weeks afterwards. Only patients with glycated haemoglobin (HbA1c) \< 9% were to be included in the study; mean HbA1c was 7.5% \[[@CR69]\]. Approximately 59% of patients were receiving gliclazide MR in combination with at least one other oral glucose-lowering drug (most commonly metformin or a DPP-4i), but 41% received gliclazide MR as monotherapy. The primary endpoint was the development of symptomatic hypoglycaemia (confirmed or unconfirmed), but patients were asked to check their blood glucose during a hypoglycaemic episode to confirm that the symptoms were caused by hypoglycaemia.

The average dose of gliclazide MR during the study was 74 mg; approximately two-thirds of patients (66%) took 60 mg, 7% took 90 mg and 22% took 120 mg. Patients fasted for an average of 15 h a day for 28.7 days. Only 62 patients (5%) broke their fast for more than 3 consecutive days, but this was mostly for non-medical reasons (*n* = 45) or medical reasons other than hypoglycaemia (*n* = 15); three patients broke their fast due to hypoglycaemia. While hypoglycaemia was more common during Ramadan than in the weeks before or after the fast, the overall rate of symptomatic hypoglycaemia during Ramadan was low (2.2% compared with 0.2% before and 0.3% after Ramadan), as was the rate of confirmed hypoglycaemia (1.6% vs. 0.2% before and \< 0.1% after Ramadan). Confirmed hypoglycaemia during Ramadan was much more common among patients who ate ≤ 2 meals per day compared with patients who ate \> 2 meals per day during Ramadan. No severe hypoglycaemic events occurred \[[@CR69]\].

Other outcomes supported the efficacy and safety of gliclazide MR during Ramadan: both HbA1c and bodyweight showed small but significant reductions, no drug-related adverse events occurred and no patient required a dose modification \[[@CR69]\]. The DIA-RAMADAN study suggests that gliclazide MR is a safe and effective treatment option for T2DM patients who wish to fast during Ramadan.

Use of Sulfonylureas in Patients with MODY {#Sec9}
==========================================

Maturity-onset diabetes of the young (MODY) was first described in the 1960s and 1970s as a form of diabetes that developed in young people (generally at an age \< 25 years) but which was distinct from type 1 diabetes because there was clear evidence of genetic inheritance and patients did not require insulin \[[@CR70], [@CR71]\]. It was subsequently determined that MODY is a form of monogenic diabetes with autosomal dominant inheritance in which the major phenotypic trait is impaired insulin secretion \[[@CR70], [@CR71]\]. More than one subtype of MODY exists, depending on the affected gene, but the most common forms are MODY2 and MODY3, which together account for about 70% of cases, followed by MODY1, MODY5 and MODY10 (Table [4](#Tab4){ref-type="table"}) \[[@CR70], [@CR72], [@CR73]\].Table 4Genetics and clinical features of selected subtypes of maturity onset diabetes of the youngSubtype^a^Affected geneLocusClinical featuresMODY1*HFN4A*20q12-q13.1Represents  approx. 10% of MODY casesNear-normal FPG but abnormal PPG, although FPG worsens over timeResponds well to sulfonylurea agentsMODY2*GCK*7p15-p13Represents approx. 32% of MODY casesMild fasting hyperglycaemia often detected incidentally\< 50% of carriers have overt diabetes mellitus and microvascular complications are rareMODY3*HNF1A*12q24.2Most common form (approx.  52% of cases)Presents clinically like MODY1MODY5*HNF1B*17cen-q21.3Represents approx. 6% of MODY casesOvert diabetes mellitus in association with renal and genitourinary abnormalitiesMODY10*INS*11p15.5Rare (\< 1% of cases)Usually associated with neonatal diabetesMODY12*ABCC8*11p15.1Rare (\< 1% of cases)Usually associated with neonatal diabetes*FPG* Fasting plasma glucose, *MODY* maturity onset diabetes of the young, *PPG* postprandial plasma glucose^a^References: \[[@CR70], [@CR73], [@CR79]\]

It is important for clinicians to be alert to the possibility of MODY in a young person with diabetes. The principal pathogenic defect in MODY is impaired insulin secretion, so (unlike patients with type 1 diabetes) 99% of patients with MODY will not have islet cell autoantibodies, and most will show endogenous insulin secretion for some years after diagnosis \[[@CR73]\]. As a result, these patients do not require insulin therapy, and those with MODY1 or MODY3 will respond very well to sulfonylureas, which are the agents of choice in these forms of MODY \[[@CR73]\]. A summary of the clinical features of MODY that can assist with differential diagnosis is shown in Table [5](#Tab5){ref-type="table"}. If MODY is suspected, genetic testing should be undertaken to confirm the diagnosis and to help guide treatment decisions \[[@CR72], [@CR74]\].Table 5Features of maturity onset diabetes of the young that can assist with differential diagnosisYoung age at onset (usually but not exclusively \< 25 years)Usually non-obese, normotensive and without elevated lipid levelsClear pattern of inheritance---diabetes present in at least three generations of family, and usually in parents and siblingsAutoantibodies to pancreatic islet cells almost always absentInsulin reserve evident for some years after diagnosisGlycosuria at lower than usual blood glucose levels (MODY1, 3 and 5)Marked sensitivity for sulfonylureas (MODY1, 3 and 5)Reference: \[[@CR73]\]

MODY caused by *HFN* mutations (MODY1, MODY3 and MODY5) responds extremely well to sulfonylureas \[[@CR73]\]. These agents should be used as first-line treatment before metformin in patients with MODY because these patients do not have insulin resistance; metformin, as an insulin sensitizer, is better suited for patients with T2DM. This was clearly demonstrated in a crossover trial in which patients with T2DM or MODY3 were randomised to metformin or gliclazide for 6 weeks, and then crossed over to the alternative treatment following a 1-week washout period between treatments \[[@CR75]\]. Gliclazide was significantly more effective in lowering fasting plasma glucose in the patients with MODY3 than it was in the patients with T2DM, whereas metformin was slightly (but not significantly better) in the T2DM than the MODY3 group (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR75]\]. In addition, while gliclazide increased β-cell function by 55% in patients with T2DM, the increase was 310% in patients with MODY3 \[[@CR75]\].Fig. 3Change in fasting plasma glucose level after 6 weeks of treatment with gliclazide or metformin in patients with type 2 diabetes or maturity-onset diabetes of the young subtype 3 (MODY3; HNF-1α diabetes) \[[@CR75]\]. Vertical lines indicate 95% confidence intervals. (Reprinted from Lancet., \[[@CR75]\] Copyright (2003), with permission from Elsevier)

The profile of T2DM in South Asia, including India, differs from that in Western populations, with a propensity to develop insulin resistance at a younger age and lower body mass index, and a high prevalence of several high-risk genetic polymorphisms \[[@CR76], [@CR77]\]. There is also evidence that the epidemiology of MODY differs in India compared with European populations \[[@CR78]\]. Genomic data from South India show that, while MODY3 was the most common subtype (as it is elsewhere), the next most common was MODY12, which is associated with a mutation in *ABCC8*, which is rare in European populations \[[@CR78]\]. Since MODY subtype can impact treatment choice, it is important to understand the prevalence of different subtypes in different populations, so a nationwide study of MODY in India is being undertaken.

This Pan-India MODY study is being conducted throughout India between November 2019 and October 2021. There are two parts to the study. Part 1 is a comprehensive genetic screening program for MODY to identify the prevalence of different subtypes, but there is also a substudy within part 1 aimed at investigating whether it is feasible to conduct genetic testing on saliva samples, since it is easier to collect saliva than blood, especially in children. Part 2 is a trial with gliclazide MR 60 mg in patients with MODY1, MODY3 or MODY12 to investigate the efficacy (primary objective) and safety (secondary objective) of this treatment. Results of this Pan-India MODY study will provide important information about the prevalence of MODY and the effect of treatment with gliclazide MR 60 mg in patients with MODY.

Conclusions {#Sec10}
===========

Sulfonylureas are effective, well-tolerated and inexpensive treatments for T2DM, and are recommended as add-on therapy in evidence-based international consensus reports. These agents are also the first-line treatment of choice in the majority of patients with MODY. Among the available sulfonylureas, gliclazide is associated with the greatest beneficial impact on cardiovascular mortality, and the lowest incidence of severe hypoglycaemia. It is hoped that the results from the DIA-RAMADAN study and other analyses will provide new data on gliclazide MR and other second-line therapies.
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